Q32 Bio (QTTB) Amortization of Deferred Charges (2023 - 2026)
Q32 Bio (QTTB) recorded quarterly Amortization of Deferred Charges of $33000.0 in Q1 2026, down 10.81% quarter-over-quarter from $37000.0 in Q4 2025, and down 31.25% on a YoY basis from $48000.0 in Q1 2025.
Q32 Bio (QTTB) Amortization of Deferred Charges (2023 - 2026) Analysis & Trends
Q32 Bio's Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $33000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 31.25% year-over-year to $33000.0; the TTM figure through Mar 2026 stood at $165000.0 (down 22.54% YoY), while the FY2025 annual figure was $180000.0, down 7.22% from the prior year.
- Amortization of Deferred Charges was $33000.0 for Q1 2026 at Q32 Bio, down from $37000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $66000.0 in Q2 2024 to a low of $7000.0 in Q3 2023.
- Historically, Amortization of Deferred Charges has averaged $38000.0 across 4 years, with a median of $37000.0 in 2025.
- The sharpest annual moves came in 2024 and 2026: Amortization of Deferred Charges jumped 614.29% in 2024, then tumbled 31.25% in 2026.
- A 4-year view of Amortization of Deferred Charges shows it stood at $30000.0 in 2023, then soared by 63.33% to $49000.0 in 2024, then slipped by 24.49% to $37000.0 in 2025, then retreated by 10.81% to $33000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $33000.0 (Q1 2026), $37000.0 (Q4 2025), and $46000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Q32 Bio | 177.18 Mn | 126.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33,000.00 |
| Mar 31, 2026 | 33,000.00 |
| Dec 31, 2025 | 37,000.00 |
| Dec 31, 2025 | 37,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Sep 30, 2025 | 46,000.00 |
| Jun 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 49,000.00 |
| Mar 31, 2025 | 48,000.00 |
| Mar 31, 2025 | 48,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Sep 30, 2024 | 50,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Mar 31, 2024 | 29,000.00 |
| Mar 31, 2024 | 29,000.00 |
| Dec 31, 2023 | 30,000.00 |
| Dec 31, 2023 | 30,000.00 |